Atrial fibrillation - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Atrial fibrillation - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Atrial fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Atrial fibrillation: Overview
Atrial fibrillation (AF or AFib) is the most common irregular heart rhythm that starts in the atria. Instead of the SA node (sinus node) directing the electrical rhythm, many different impulses rapidly fire at once, causing a very fast, chaotic rhythm in the atria. As the electrical impulses are so fast and chaotic, the atria cannot contract and/or squeeze blood effectively into the ventricle. AF is an irregular and often rapid heart rate that occurs when the two upper chambers of the heart experience chaotic electrical signals. The result is a fast and irregular heart rhythm. The heart rate in AF may range from 100 to 175 BPM. The normal range for a heart rate is 60–100 BPM. A major concern with atrial fibrillation is the potential to develop blood clots within the upper chambers of the heart. These blood clots forming in the heart may circulate to other organs and lead to blocked blood flow (ischemia).
'Atrial fibrillation - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial fibrillation pipeline landscape is provided which includes the disease overview and Atrial fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Atrial fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atrial fibrillation Emerging Drugs
Further product details are provided in the repor
Atrial fibrillation: Therapeutic Assessment
This segment of the report provides insights about the different Atrial fibrillation drugs segregated based on following parameters that define the scope of the report, such as:
Atrial fibrillation: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrial fibrillation therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial fibrillation drugs.
Atrial fibrillation Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Atrial fibrillation - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Atrial fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Atrial fibrillation: Overview
Atrial fibrillation (AF or AFib) is the most common irregular heart rhythm that starts in the atria. Instead of the SA node (sinus node) directing the electrical rhythm, many different impulses rapidly fire at once, causing a very fast, chaotic rhythm in the atria. As the electrical impulses are so fast and chaotic, the atria cannot contract and/or squeeze blood effectively into the ventricle. AF is an irregular and often rapid heart rate that occurs when the two upper chambers of the heart experience chaotic electrical signals. The result is a fast and irregular heart rhythm. The heart rate in AF may range from 100 to 175 BPM. The normal range for a heart rate is 60–100 BPM. A major concern with atrial fibrillation is the potential to develop blood clots within the upper chambers of the heart. These blood clots forming in the heart may circulate to other organs and lead to blocked blood flow (ischemia).
'Atrial fibrillation - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial fibrillation pipeline landscape is provided which includes the disease overview and Atrial fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Atrial fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial fibrillation.
This segment of the Atrial fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atrial fibrillation Emerging Drugs
- CKD-825: Chong Kun Dang Pharmaceutical
- Gencaro: ARCA biopharma
- AGN-151607: AbbVie
- HBI-3000: HUYA Bioscience International
Further product details are provided in the repor
Atrial fibrillation: Therapeutic Assessment
This segment of the report provides insights about the different Atrial fibrillation drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Atrial fibrillation
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Nasal
- Molecule Type
- Monoclonal Antibody
- Anticoagulant
- Bacterial proteins
- Small molecule
- Gene therapy
- Cardiovascular therapy
- Product Type
Atrial fibrillation: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrial fibrillation therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial fibrillation drugs.
Atrial fibrillation Report Insights
- Atrial fibrillation Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Atrial fibrillation drugs?
- How many Atrial fibrillation drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial fibrillation?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atrial fibrillation therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Atrial fibrillation and their status?
- What are the key designations that have been granted to the emerging drugs?
- Chong Kun Dang Pharmaceutical
- ARCA Biopharma
- AbbVie
- HUYA Bioscience International
- Merz Pharma
- AbbVie
- OMEICOS Therapeutics
- Acesion Pharma
- Milestone Pharmaceuticals
- Verseon
- Vivasc Therapeutics
- Espero BioPharma
- CKD-825
- Gencaro
- AGN-151607
- HBI-3000
- Botulinum Toxin Type A Injection [Xeomin]
- AGN-151607
- OMT-28
- AP30663
- Etripamil
- VE-1902
- CTP-Amio
- ESP-001
Introduction
Executive Summary
Atrial fibrillation: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Atrial fibrillation – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Atrial fibrillation companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Atrial fibrillation Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
CKD-825: Chong Kun Dang
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AGN-151607: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
HBI-3000: HUYA Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Atrial fibrillation Key Companies
Atrial fibrillation Key Products
Atrial fibrillation- Unmet Needs
Atrial fibrillation- Market Drivers and Barriers
Atrial fibrillation- Future Perspectives and Conclusion
Atrial fibrillation Analyst Views
Atrial fibrillation Key Companies
Appendix
Executive Summary
Atrial fibrillation: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Atrial fibrillation – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Atrial fibrillation companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Atrial fibrillation Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
CKD-825: Chong Kun Dang
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AGN-151607: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
HBI-3000: HUYA Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Atrial fibrillation Key Companies
Atrial fibrillation Key Products
Atrial fibrillation- Unmet Needs
Atrial fibrillation- Market Drivers and Barriers
Atrial fibrillation- Future Perspectives and Conclusion
Atrial fibrillation Analyst Views
Atrial fibrillation Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Atrial fibrillation
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Atrial fibrillation
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Atrial fibrillation
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Atrial fibrillation
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
